Amended charter approves 1-for-20 reverse stock split
Quince Therapeutics adopted a 1-for-20 reverse stock split effective June 2026 following board and shareholder approval. This corporate restructuring consolidates outstanding shares to potentially bolster the market price per share.
View filing at SEC.gov →